Monitoring and Population HealthShared Care and High-Risk Medicines
Shared care, understood at a glance.
A specialist starts a high-risk medicine under shared care; Reedley organises the protocol’s monitoring, the responsible clinicians, the latest results and outstanding actions; your team acts.
Illustrative demonstration · intended workflow
Interactive demonstration
Synthetic patient · pause, step and replay at any point
- Who is responsible, for what, under which protocol.
- Monitoring due, results received and actions still outstanding, side by side.
- Evidence and audit history kept with every step.
From what arrives to what you decide
- What entersA specialist starts a high-risk medicine under shared care
- What Reedley preparesProtocol monitoring, responsibilities, latest results and outstanding actions together
- What the clinician decidesYour team acts
What it does not do · what exists today
- Reedley does not decide what a protocol requires: shared-care protocols vary between ICBs and would be configured locally.
- Monitoring and follow-up for high-risk medicines exist in the development build on synthetic data; the shared-care register itself is the intended workflow. Those monitoring rules are drafts with no clinical owner and differ from national guidance.
- Not yet in Reedley’s intended-purpose register: shown to explore the workflow, not as committed product scope.
Every patient shown is synthetic. No integration with a clinical system is claimed, and no clinician has yet used Reedley in practice. Safety and governance
See it with your own work in mind.
Tell us your role and the workflows you care about, and we will walk you through them on synthetic data.